Intervacc (IVACC) DNB Carnegie Småbolagsdag summary

Technology and product overview

• Developed a novel vaccine platform using recombinant fusion proteins, eliminating the risk of disease transmission from the vaccine itself.

• Main product, Strangvac, targets strangles (kvarka) in horses, a highly contagious and serious disease.

• Strangvac is approved in the EU, UK, and several other European countries, with distribution managed through partners and subsidiaries.

Market adoption and effectiveness

• Over 30,000 horses vaccinated in Europe, demonstrating strong safety and efficacy with minimal breakthrough cases.

• Growing support from veterinarians and key opinion leaders, with increasing scientific publications validating the vaccine.

• Strangles outbreaks are frequent and costly, with up to 10% mortality and significant operational disruptions for horse facilities.

Commercial strategy and market expansion

• Sales have more than doubled year-over-year but remain at low penetration levels; efforts are underway to boost awareness and adoption.

• Marketing is primarily directed at veterinarians due to regulatory constraints, with successful campaigns in the UK being considered for other markets.

• Recent launches in Spain, Portugal, Slovenia, and a relaunch in Italy target large equine populations.

• The vaccine is priced at about 300 SEK per dose, comparable to existing influenza vaccines, and is administered in a program with initial and booster shots.